Cerevel plots first late-stage move as Pfizer drug comes through in PhII Parkinson's trial

One of the drugs that Cerevel Therapeutics has picked up from Pfizer’s neuroscience pipeline has shown promise in a Phase II trial, paving the way for a quick advance into pivotal Parkinson’s programs.

The biotech reported on Monday that oral tavapadon (formerly PF-06649751) beat placebo in helping patients with early-stage Parkinson’s disease achieve statistically significant improvement on a score measuring their motor symptoms.